Showing 281-290 of 8879 results for "".
Treating Non-melanoma Skin Cancer: What’s New and Exciting
https://practicaldermatology.com/conferences/scale-2023/treating-non-melanoma-skin-cancer-whats-new-and-exciting/20201/Dermatologists have a host of new tools for treating advanced basal and squamous cell carcinomas. Todd Schlesinger, MD, discusses hedgehog pathway inhibitors and immunotherapy and their growing role in treating non-melanoma skin cancers.DermWireTV: USPS Task Force Skin Cancer Screening Update; The 4th Annual San Diego Dermatology Symposium; Upcoming National Botox Day, Plus More
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-usps-task-force-skin-cancer-screening-update-the-4th-annual-san-diego-dermatology-symposium-upcoming-national-botox-day-plus-more/20155/The United States Preventive Services Task Force says more research is needed before recommending screening for skin cancer in people without symptoms, an update on the Fourth Annual San Diego Dermatology Symposium, plus more top news in this episode of DermWireTV.Noah Worcester 2024: Dr. Gold on Toxins
https://practicaldermatology.com/conferences/noah-worcester-2024/noah-worcester-2024-dr-gold-toxins/24583/Noah Worcester 2024: Dr. Gold on ToxinsHow Incyte Is Following the Science to Address Unmet Needs in Immune-Mediated Skin Conditions
https://practicaldermatology.com/topics/infections-infectious-disease/how-incyte-is-following-the-science-to-address-unmet-needs-in-immune-mediated-skin-conditions/19945/Ahmad Naim, MD, Vice President of US Medical Affairs at Incyte, shares how the company’s discovery expertise in immunology is fueling research aimed at delivering innovative medicines that address the unmet needs of people living with immune-mediated dermatologic conditions, including atopic dermatiHumira Approved for HS, NewDerm LIVE Hits Hollywood
https://practicaldermatology.com/topics/psoriasis/dermwiretv-humira-approved-for-hs-newderm-live-hits-hollywood/18831/AbbVie's Humira has become the first and only FDA-approved therapy for adults with moderate to severe hidradenitis suppurativa. NewDermLIVE, a new meeting for dermatologists new to practice—and those not so new to practice—has brought a new kind of meeting into the dermatology space. Solta MedicaJournal Club: How Physicians Can Use the New AD Guidelines in Practice
https://practicaldermatology.com/series/practical-dermatology-journal-club-atopic-dermatitis/how-physicians-can-use-the-new-ad-guidelines-in-practice/24094/In this second part of the inaugural edition of Practical Dermatology's® Atopic Dermatitis (AD) Journal Club, Derek Chu, MD, a key architect of new guidelines for AD management and care, talks with Peter Lio, MD, about his vision for how to make these guidelines easy-to-use and practical for dermatoNoah Worcester 2024: Dr. Bridges on Practice Management
https://practicaldermatology.com/conferences/noah-worcester-2024/noah-worcester-2024-dr-bridges-practice-management/24580/Alina Bridges, DO, FAAD, summarizes her lecture on practice management and coding at the 2024 Noah Worcester Dermatological Society meeting.Journal Club: What's New in Pathogenesis and Treatment of Atopic Dermatitis
https://practicaldermatology.com/series/practical-dermatology-journal-club-atopic-dermatitis/journal-club-whats-new-in-pathogenesis-and-treatment-of-atopic-dermatitis/26247/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, talks with Jason E. Hawkes, MD, a dermatologist practicing in the Sacramento area, and a member of the Practical Dermatology Editorial Board, about the latest research on the pathogenesis of and treatment targets for atopic dermatitis (AD).Noah Worcester 2024: Dr. Hinshaw on Onychomycosis
https://practicaldermatology.com/conferences/noah-worcester-2024/noah-worcester-2024-dr-hinshaw-onychomycosis/24587/Molly Hinshaw, MD, FAAD, summarizes her lecture on diagnosis and management of onychomycosis at the 2024 Noah Worcester Dermatological Society meeting.New Drug Developments in Dermatology
https://practicaldermatology.com/topics/skin-cancer-photoprotection/new-drug-developments-in-dermatology/19971/Despite the COVID pandemic, the FDA had a nearly record year in drug approvals, says Vinod Nambudiri, MD, MBA, which has translated to new developments in dermatology. He discusses approvals of tirbanibulin 1% ointment for actinic keratoses and clascoterone cream 1% for acne, and how they fit into t